{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:40:46Z","timestamp":1790336446710,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Motac Neuroscience Ltd"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.neuropharm.2016.07.012","type":"journal-article","created":{"date-parts":[[2016,7,16]],"date-time":"2016-07-16T15:04:23Z","timestamp":1468681463000},"page":"48-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"PA","title":["An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models"],"prefix":"10.1016","volume":"110","author":[{"given":"Wai Kin D.","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-7357","authenticated-orcid":false,"given":"Sandrine M.","family":"Camus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa Y.","family":"Pioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-4638","authenticated-orcid":false,"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2016.07.012_bib1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0166-2236(90)90107-L","article-title":"Functional architecture of basal ganglia circuits: neural substrates of parallel processing","volume":"13","author":"Alexander","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.ne.09.030186.002041","article-title":"Parallel organization of functionally segregated circuits linking basal ganglia and cortex","volume":"9","author":"Alexander","year":"1986","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","article-title":"Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia","volume":"57","author":"Aubert","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A(2A) receptor antagonist treatment of Parkinson's disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","article-title":"Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease","volume":"132","author":"Bastide","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm875","article-title":"Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function","volume":"9","author":"Bezard","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-4886(03)00250-4","article-title":"A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease","volume":"184","author":"Bibbiani","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/syn.20539","article-title":"Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain","volume":"62","author":"Brooks","year":"2008","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.07.012_bib10","first-page":"40","article-title":"Quantitative assessment of dyskinesias in subhuman primates","volume":"14","author":"Brotchie","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/mds.870030207","article-title":"An investigation of the phenomenon of \u201cset\u201d in Parkinson's disease","volume":"3","author":"Brown","year":"1988","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0166-2236(90)90058-I","article-title":"Cognitive function in Parkinson's disease: from description to theory","volume":"13","author":"Brown","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/brain\/awh128","article-title":"Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias","volume":"127","author":"Calon","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nlm.2015.06.012","article-title":"Why bother using non-human primate models of cognitive disorders in translational research?","volume":"124","author":"Camus","year":"2015","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2012.08.030","article-title":"Istradefylline, an adenosine A(2)A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis","volume":"324","author":"Chen","year":"2013","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2005.03.024","article-title":"Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease","volume":"30","author":"Cools","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"Pt 5","key":"10.1016\/j.neuropharm.2016.07.012_bib18","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1093\/brain\/114.5.2095","article-title":"Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability","volume":"114","author":"Cooper","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/0028-3932(89)90128-0","article-title":"Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction","volume":"27","author":"Downes","year":"1989","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-013-0066-7","article-title":"Istradefylline: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2009.06.008","article-title":"Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial","volume":"16","author":"Fernandez","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.neuroscience.2015.04.027","article-title":"Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease","volume":"298","author":"Fidalgo","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/jnnp.48.6.517","article-title":"The effect of Parkinson's disease on the ability to maintain a mental set","volume":"48","author":"Flowers","year":"1985","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib24","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.25133","article-title":"A\u00a0critique of available scales and presentation of the non-human primate dyskinesia rating scale","volume":"27","author":"Fox","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0361-9230(01)00501-9","article-title":"Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats","volume":"55","author":"Gevaerd","year":"2001","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib26","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1523\/JNEUROSCI.4223-07.2007","article-title":"RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease","volume":"27","author":"Gold","year":"2007","journal-title":"J.\u00a0Neurosci."},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2016.07.012_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/brain\/111.2.299","article-title":"\u2018Frontal\u2019 cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa","volume":"111","author":"Gotham","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib28","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","article-title":"Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys","volume":"52","author":"Grondin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib29","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1523\/JNEUROSCI.5059-04.2005","article-title":"Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia","volume":"25","author":"Guigoni","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","article-title":"Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD","volume":"61","author":"Hauser","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib31","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/mds.22095","article-title":"Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations","volume":"23","author":"Hauser","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib33","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1212\/WNL.37.8.1371","article-title":"Fluctuations in plasma dopamine level impair memory in Parkinson's disease","volume":"37","author":"Huber","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib34","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1212\/WNL.39.3.438","article-title":"Dose-dependent memory impairment in Parkinson's disease","volume":"39","author":"Huber","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib35","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/01.WNL.0000095209.59347.79","article-title":"A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD","volume":"61","author":"Jenner","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.parkreldis.2008.12.006","article-title":"Adenosine, adenosine A 2A antagonists, and Parkinson's disease","volume":"15","author":"Jenner","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-013-3158-x","article-title":"Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex","volume":"230","author":"Kadowaki Horita","year":"2013","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys","volume":"43","author":"Kanda","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/exnr.2000.7350","article-title":"Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys","volume":"162","author":"Kanda","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neulet.2014.02.027","article-title":"Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease","volume":"566","author":"Ko","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib41","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/mds.25859","article-title":"Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"29","author":"Ko","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNF.0000000000000073","article-title":"A\u00a0long-term study of istradefylline safety and efficacy in patients with Parkinson disease","volume":"38","author":"Kondo","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"Pt 6","key":"10.1016\/j.neuropharm.2016.07.012_bib43","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/brain\/119.6.2121","article-title":"Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels","volume":"119","author":"Kulisevsky","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib44","first-page":"83","article-title":"Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease","volume":"14","author":"Lees","year":"2008","journal-title":"CNS Neurosci. Ther."},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2016.07.012_bib45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/brain\/106.2.257","article-title":"Cognitive deficits in the early stages of Parkinson's disease","volume":"106","author":"Lees","year":"1983","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1212\/WNL.39.4.557","article-title":"Cognitive impairments associated with early Parkinson's disease","volume":"39","author":"Levin","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","article-title":"Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)","volume":"63","author":"Lewitt","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib48","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.2003.01632.x","article-title":"Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia","volume":"84","author":"Lundblad","year":"2003","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib49","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2967\/jnumed.108.051474","article-title":"Brain adenosine A2A receptor occupancy by a novel A1\/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect","volume":"49","author":"Mihara","year":"2008","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib50","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.23107","article-title":"Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study","volume":"25","author":"Mizuno","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib51","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.25418","article-title":"Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease","volume":"28","author":"Mizuno","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pneurobio.2007.07.001","article-title":"Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications","volume":"83","author":"Morelli","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib53","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1212\/01.WNL.0000095211.71092.A0","article-title":"Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists","volume":"61","author":"Mori","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib54","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1073\/pnas.93.3.1325","article-title":"Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys","volume":"93","author":"Murphy","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1017\/S1355617709090614","article-title":"Cognitive decline in Parkinson's disease: a prospective longitudinal study","volume":"15","author":"Muslimovic","year":"2009","journal-title":"J.\u00a0Int. Neuropsychol. Soc."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4522(00)00250-5","article-title":"Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study","volume":"100","author":"Ochi","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuroscience.2004.04.050","article-title":"Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease","volume":"127","author":"Ochi","year":"2004","journal-title":"Neuroscience"},{"issue":"Pt 6","key":"10.1016\/j.neuropharm.2016.07.012_bib58","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/brain\/115.6.1727","article-title":"Fronto-striatal cognitive deficits at different stages of Parkinson's disease","volume":"115","author":"Owen","year":"1992","journal-title":"Brain"},{"issue":"Pt 5","key":"10.1016\/j.neuropharm.2016.07.012_bib59","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/brain\/116.5.1159","article-title":"Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease","volume":"116","author":"Owen","year":"1993","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib60","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40263-014-0161-7","article-title":"Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued","volume":"28","author":"Pinna","year":"2014","journal-title":"CNS drugs"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib61","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/syn.20410","article-title":"Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease","volume":"61","author":"Pinna","year":"2007","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib62","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ana.410290616","article-title":"High-speed memory scanning in Parkinson's disease: adverse effects of levodopa","volume":"29","author":"Poewe","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib63","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1172\/JCI59426","article-title":"PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking","volume":"122","author":"Porras","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib64","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.parkreldis.2011.09.023","article-title":"Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study","volume":"18","author":"Pourcher","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/01.fbp.0000166825.62130.9a","article-title":"Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpine-treated rats","volume":"16","author":"Prediger","year":"2005","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib66","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib67","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.wnl.0000266670.35219.0c","article-title":"The neuroprotective effects of caffeine: a prospective population study (the Three City Study)","volume":"69","author":"Ritchie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib68","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/brain\/awn112","article-title":"Parkinson's disease and dopaminergic therapy\u2013differential effects on movement, reward and cognition","volume":"131","author":"Rowe","year":"2008","journal-title":"Brain"},{"issue":"Pt 3","key":"10.1016\/j.neuropharm.2016.07.012_bib69","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/brain\/111.3.695","article-title":"A\u00a0comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease","volume":"111","author":"Sahakian","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","article-title":"Adenosine A2A receptors and basal ganglia physiology","volume":"83","author":"Schiffmann","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib71","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1471-4159.1991.tb08257.x","article-title":"Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study","volume":"57","author":"Schiffmann","year":"1991","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-3940(91)90391-6","article-title":"Distribution of adenosine A2 receptor mRNA in the human brain","volume":"130","author":"Schiffmann","year":"1991","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib73","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1523\/JNEUROSCI.13-03-01080.1993","article-title":"Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons","volume":"13","author":"Schiffmann","year":"1993","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0006-8993(90)90108-N","article-title":"Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys","volume":"534","author":"Schneider","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0006-8993(90)90069-N","article-title":"Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys","volume":"519","author":"Schneider","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib76","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/mds.25258","article-title":"Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model","volume":"28","author":"Schneider","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib77","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbr.2010.03.040","article-title":"Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism","volume":"211","author":"Schneider","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib78","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/jpet.103.051912","article-title":"The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys","volume":"306","author":"Schneider","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib79","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0022-3565(24)34957-2","article-title":"Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys","volume":"290","author":"Schneider","year":"1999","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib80","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","article-title":"What contributes to quality of life in patients with Parkinson's disease?","volume":"69","author":"Schrag","year":"2000","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib81","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0010-9452(13)80353-X","article-title":"Distractibility in early Parkinson's disease","volume":"26","author":"Sharpe","year":"1990","journal-title":"Cortex"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib82","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.neuron.2015.10.039","article-title":"M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-induced dyskinesia","volume":"88","author":"Shen","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib83","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/WNL.25.12.1144","article-title":"On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients","volume":"25","author":"Shoulson","year":"1975","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib84","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.expneurol.2006.05.015","article-title":"Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists","volume":"202","author":"Simola","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib85","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000313834.22171.17","article-title":"A\u00a012-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease","volume":"70","author":"Stacy","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib86","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0306-4522(97)00510-1","article-title":"Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons","volume":"84","author":"Svenningsson","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib87","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0028-3932(99)00103-7","article-title":"Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication","volume":"38","author":"Swainson","year":"2000","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuropharm.2016.07.012_bib88","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2741\/2870","article-title":"Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies","volume":"13","author":"Takahashi","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib89","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-801022-8.00008-8","article-title":"Effects of the adenosine A2A receptor antagonist on cognitive dysfunction in Parkinson's disease","volume":"119","author":"Uchida","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2015.09.028","article-title":"The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets","volume":"766","author":"Uchida","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.07.012_bib91","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/brain\/awm111","article-title":"Evolution of cognitive dysfunction in an incident Parkinson's disease cohort","volume":"130","author":"Williams-Gray","year":"2007","journal-title":"Brain"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816302982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816302982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:46:22Z","timestamp":1758437182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390816302982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":91,"alternative-id":["S0028390816302982"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.07.012","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}